The Keto Cholesterol Study Has Gone HORRIBLY Wrong

Stanfield grounds this protocol in the foundational epidemiological and genetic evidence that underpins clinical lipidology. He cites the 2017 European Heart Journal meta-analysis that combined over 200 prospective studies and trials, demonstrating a remarkably consistent, log-linear relationship between absolute LDL exposure and cardiovascular events. Every major medical society—cardiology guidelines, medical schools, hospitals—teaches that lower LDL is better. He contrasts this consensus with the fringe narrative propagated by the keto CTA authors that high LDL in LMHRs is somehow safe. The protocol he practices daily is not extreme; it is standard-of-care preventive medicine. He emphasizes that he wants to prevent disease rather than treat it, meaning he intervenes before a patient has a myocardial infarction. The keto CTA data, where LMHR plaque progressed far faster than expected, reinforces this strategy because it shows that even young, lean individuals with sky-high LDL are not immune—they are accumulating disease silently. Stanfield’s frustration stems from the difficulty of implementing this protocol when patients have been preconditioned to mistrust it. He must spend disproportionate time deconstructing bad faith or poorly reported research, often losing the battle. By framing LDL lowering as an urgent, evidence-backed necessity, he hopes to counteract that tide.

The keto CTA study was pre-registered with a pre-specified primary outcome: percentage change in non-calcified coronary plaque volume. This is the key metric to prove or disprove the hypothesis. When the paper came out, however, the results section provided only a pixelated graph—no raw numbers, no statistical analysis. It took massive social media pressure to force the authors to release the actual figure: 18.8 units, more than double the 7-unit conservative estimate they themselves had published beforehand. Stanfield points out that this violates basic clinical trial reporting standards. Every study must present its primary outcome clearly in written form with statistics. The fact that the authors hid it and then posted the 18.8 alongside a meme suggests they were trying to spin a damaging result. The plaque progression was not just higher than expected; it was alarmingly high when compared to external cohorts. The failure to truthfully report the primary outcome undermines any subsequent interpretation that downplays the danger of high LDL in these individuals.

Stanfield overlays the keto CTA outcome onto other known data. He references the PARADIGM study, where high-risk individuals' atheroma volume was tracked over 10 years, allowing estimation of yearly percentage change. When the keto CTA progression is plotted against that, the LMHRs' plaque grew faster than even the high-risk groups. He also compares it to cohort data: non-diabetics progressed 2.8 units/year, diabetics 34.3. The keto participants, at 18.8, are roughly in between—much closer to the diseased group than to the healthy one. This is especially alarming because LMHRs were specifically selected as being lean, young, and without traditional cardiovascular risk factors except for their extreme lipid profile. The finding directly challenges the notion that their high LDL is somehow protective or irrelevant. Instead, it suggests that the diet-induced hypercholesterolemia is driving real, measurable atherosclerosis at an accelerated pace. Stanfield emphasizes that this should be a wake-up call, not a meme.

Stanfield describes seeing the consequences in primary care. Patients come in with very high LDL cholesterol—sometimes over 500 mg/dL—and refuse statins or lifestyle changes because they've heard from influencers that their 'lean mass hyperresponder' status protects them. The study authors' social media narrative focuses on the lack of a dose-response between LDL levels and progression within the already high range, ignoring that all these patients are progressing rapidly. This is clinically irrelevant: the point is that plaque is building up fast, regardless of whether the person at 400 mg/dL progressed the same as someone at 500 mg/dL. Stanfield compares a 15-minute consultation to years of curated online content and admits he often fails to change minds. He is visibly frustrated and mentions that he personally knows people—patients he could not convince—who went on to have heart attacks and strokes that might have been avoided if their lipids had been managed. This is the human cost of the study's poor reporting and the subsequent memeifying of a serious health risk.